Dr. Ethan Perlstein - Podcast Details

Shows

The Healthy EnterpriseBiotech on the Blockchain: Rare Disease Solutions with Dr. Ethan PerlsteinIn this episode, we interview Dr. Ethan Perlstein, founder and CEO of Curetopia, about his mission to end rare genetic diseases. Dr. Perlstein shares his journey as a scientist, builder, and investor, and discusses Curetopia's innovative approach to drug development, including the use of blockchain and Web3 technologies. He emphasizes the urgency of addressing rare diseases and the need for new models to accelerate the search for cures.Chapters/Timestamps:00:00 - Introduction and Dr. Ethan Perlstein's Background 08:50 - The Challenge of Rare Diseases 21:25 - Curetopia's Mission and Approach 31:54 - Blockchain and the Future of Drug Developme...2025-04-1643 min

The DeSci PodcastDecentralized Science vs. Rare Diseases: A Game-Changer? | Ethan PerlsteinWelcome to another episode of the DeSci Podcast. Today, we are discussing a critical issue that affects over 30 million people in the United States—Rare Diseases. Despite being more prevalent than cancer and HIV combined, rare diseases remain underfunded, overlooked by Big Pharma, and trapped in a broken system.Our Guest: This episode features Ethan Perlstein, founder of CureTopia, an initiative using Decentralized Science (DeSci) and blockchain to revolutionize rare disease research. Why does the current system fail millions of patients, and how can decentralized models change that?What You’ll Learn in This Episode:-The reality of rare dise...2025-03-241h 00

Biotech HangoutEpisode 90On this week’s Biotech Hangout, hosts Daphne Zohar, Tim Opler, Dawn Bell, Ethan Perlstein and Eric Schmidt discuss the latest in biotech news, including the overall performance of IPOs this year, including Metagenomi’s IPO this week and what it means for the IPO window. The hosts also debate the value of tracking 13Fs as an investment strategy, M&A news including Gilead’s $4.3B acquisition of CymaBay, plus offerings and some related data for Larimar ($150M offering and Phase 2 data), PRIME Medicine ($140M offering), Sana ($165M offering), Crispr ($250M offering) and KalVista ($160M offering and Phase 3 data). The gr...2024-02-2859 min

Biotech HangoutEpisode 81On this week’s episode of Biotech Hangout hosts Daphne Zohar, Tim Opler, Josh Schimmer, Chris Garabedian, John Maraganore and Ethan Perlstein discuss the latest industry news including takeaways and sentiment from the recent Jefferies, Stifel, American Heart Association and ACR conferences. They also discuss Ajinomoto acquiring Forge Biologics ($620M), Crispr and Vertex MHRA approval in the UK, Verve data and Novo Nordisk’s SELECT trial details. They hosts discuss Astellas’ acquisition of Propella ($175M) and the differences between Propella and PureTech’s lymphatic-focused technologies, on the back of PureTech’s Phase 2 data. Other topics include three merger agreements: Graphite B...2024-01-0457 min

Biotech HangoutEpisode 69On Biotech Hangout this week, Brad Loncar, Chris Garabedian, Sam Fazeli, Rob Perez and Ethan Perlstein discuss the influence of GLP-1s including cost, safety, drawbacks and more in light of Novo Nordisk’s positive semaglutide SELECT study results and Eli Lilly’s earnings, which rose due to their type 2 diabetes drug. Other big topics include last week’s Sage and Biogen news following the FDA’s decision to approve zuranolone for PPD but not MDD and its effect on Sage’s stock, plus progress and setbacks in ultra rare diseases including Taysha Gene Therapies. The hosts also dive into Iveri...2023-08-1759 min

Biotech HangoutEpisode 47This week, hosts Daphne Zohar, Josh Schimmer, Dawn Bell and Sam Fazeli cover recent biotech earnings, big pharma revenue drivers, FDA news, data and much more. The group kicks off the conversation by addressing the slow week in M&A news before diving into the profitability of Medicare Advantage for private insurance and the new RADV rule updates announced – they also touch on how this rule will impact the future of pharma. Additionally, the hosts cover big pharma patent expiries & pipeline sourcing needs. Notable earnings updates from big pharma are discussed and the group shares their thoughts on Amgen’s Am...2023-02-0658 min

Biotech HangoutEpisode 46On this week’s episode, hosts Daphne Zohar and Josh Schimmer welcome founder and former CEO of Alnylam, John Maraganore, as a guest, and are joined by Ethan Perlstein, Rob Perez, Michal Preminger and Chris Garabedian. The discussion begins with a recap from John’s recent op-ed article published in The Timmerman Report that poses the question: ‘Is it the right time for biotech to be back together in person?’ The group debates the subject of remote vs. hybrid work models and discusses other cultural and strategic topics related to business models in biotech. They also cover Amazon’s new progra...2023-02-061h 01

Biotech HangoutEpisode 39Jeremy Levin, Bruce Booth, Rob Perez, Dawn Bell and Ethan Perlstein join Daphne and Josh to discuss the macro biotech picture, recap the recent Jefferies Conference, discuss the impact of partisanship in healthcare legislation (including IRA), the coming impact for private and crossover investors, the Acrivon Therapeutics IPO & other recent financings, the Editas clinical setback and some recent FDA approvals, and the a16z story about the biggest company in the world being a consumer health tech company. The group also debates what makes a great biotech CEO and how those CEOs should handle company setbacks. Community...2022-11-281h 03

Biotech 2050 Podcast77. Battling rare diseases: patients and scientists, Ethan Perlstein, Founder and CEO, PerlaraDr. Ethan Perlstein is the founder and CEO of Perlara PBC, the first biotech public benefit company established in 2014 that partners with highly motivated and entrepreneurial families and foundations to develop treatments and cures for genetic diseases. Ethan is also cofounder and CEO of Maggie's Pearl LLC, a joint venture co-owned by Perlara, a family based in Michigan and the Mayo Clinic that is commercializing a repurposed drug for a congenital disorder of glycosylation. Ethan relaunched Perlara in 2021 as the first fully decentralized, distributed and web3 biotech company.2021-10-2726 min

Once Upon A GeneFive Common Errors Made by Recently Diagnosed, Emotionally Overwhelmed Families Without Monetary Resources or Connections with Perlara Founder and CEO - Ethan PerlsteinONCE UPON A GENE - EPISODE 098Five Common Errors Made by Recently Diagnosed, Emotionally Overwhelmed Families Without Monetary Resources or Connections with Perlara Founder and CEO - Ethan PerlsteinEthan Perlstein is Founder of Perlara and on Clubhouse every Tuesday and Thursday in the Gene Fixers Club. EPISODE HIGHLIGHTSWhat inspired your work as an entrepreneurial scientist at Perlara?It started at a professional crossroads when my sister received a rare disease diagnosis and it opened my eyes to the r...2021-09-0242 min

17 Minutes of ScienceEpisode 43: rare Disease Drug Development with Dr. Ethan Perlstein (Founder & CEO of Perlara PBC)For episode 43 of 17 Minutes of Science we are joined by Dr. Ethan Perlstein of Perlara PBC. Dr. Perlstein is the CEO and founder of Perlara, a company on a mission to accelerate the discovery of cures for rare genetic diseases and uncover underlying mechanisms that enable the development of treatments that work across a range of diseases and individuals. Ethan has been passionate about Rare Disease for more than a decade. Starting with PhD in Harvard's Stuart Schreiber lab. Then, as a postdoctoral fellow in the Lewis-Sigler Institute at Princeton, Ethan has been championing finding...2021-04-2017 min

The Good AI Podcast#7 Perlara CEO Ethan Perlstein on New Models in BiopharmaCEO, cure sherpa, and entrepreneur-scientist Ethan Perlstein joins us to talk about how Biopharma PBC Perlara works with families, patient organizations, and researchers to develop cures for rare diseases. In this podcast, we learn how it all got started, how Perlara is taking a novel approach to the traditional Pharma business model to create recurring revenue models which Do Well by Doing Good, and end with some advice for listeners looking to follow a similar approach. Learn more @ https://www.perlara.com/ or Tweet Ethan @eperlste 2021-02-0923 min

Improbable DevelopmentsEthan Perlstein: Scientific Coaching for Rare FamiliesWe first met Dr. Ethan Perlstein on our other podcast Raising Rare. Dr. Perlstein is a biotechnology entrepreneur. Dr. Perlstein has nearly two decades of experience in biomedical research and over five years in biotech company formation and executive leadership. He holds a doctorate in molecular and cell biology from Harvard University and was a Lewis-Sigler Fellow at Princeton University from 2007-2012.In 2014, Dr. Perlstein founded Perlara PBC, the first biotech public benefit corporation with a legal mandate to co-develop drugs in collaboration with families and communities affected by genetic diseases. During that time, Dr. Pe...2020-11-1616 min

Raising RareDr. Ethan Perlstein Discusses Drug Repurposing for Rare DiseasesOne of our goals for Raising Rare is to introduce some of the scientists who are working on finding treatments for Raghav. Another goal is to educate our listeners about finding and developing treatments. In this episode Sanath and I spend some time with Dr Ethan Perlstein talking about various animal models that can be used to screen for active drugs. Dr. Perlstein is the CEO of Perlara, a Public Benefit Corporation that is dedicated to helping families seek treatments for rare genetic diseases. He is also one of the original members of the cureGPX4 Scientific Team. ...2020-10-1035 min

U2FP CureCastCureCast Episode 42 with Dr. Ethan PerlsteinJason and Matthew interview Dr. Ethan Perlstein, formerly the Chief Science Officer at the Christopher and Dana Reeve Foundation and Founder of Perlara. We talk about Ethan’s work to develop a ‘roadmap to cures for paralysis’, along with his experience, reception and impressions for where the cure movement can and should go next. BIO: Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlst...2020-07-101h 11

A Case of the MondaysBiology is Technology (w/ Ryan Bethancourt)Today, Chris sits down with Ryan Bethencourt, CEO of Wild Earth Inc, to talk about science fiction, biohacking, the birth of biotech and disrupting one of the oldest industries on the planet. Chris also talks grill etiquette, retreats, and tells you to eat a GMO salad. You can follow Ryan on Twitter and Instagram at @RyanBethencourt; Wild Earth can be found at @wildearthpetsFor more cutting edge biotech companies, check out Indiebio, the biotech accelerator that Ryan co-founded.If you want to get inspired by some science fiction, here's a list to start...2019-06-031h 10

Talking Precision MedicineThe organic intelligence of families in need with Ethan Perlstein | Talking Precision Medicine #04In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling of disease biology… to help accelerate the discovery and de-risk the development of novel therapeutics.2019-01-0830 min

The Long Run with Luke TimmermanEp18: Ethan PerlsteinEp18: Ethan Perlstein by Timmerman Report 2018-05-091h 04

RARECastLessons from Pitching Venture CapitalistsStories abound about plucky entrepreneurs financing their startups, but it’s unusual to get trench-view insights from founders who have slogged their way through endless pitches along Sand Hill Road. Ethan Perlstein, founder and CEO of the rare disease drug discovery company Perlara, shared what he gleaned from his recent $7.4 million equity round for his company in a piece on the CNBC website. We spoke to Perlstein about his experience, what he learned in the process, and his practical advice for entrepreneurs seeking funding.2017-11-1520 min

The Bio ReportNovartis Deal Validates Perlara's Approach to Rare Disease Drug DiscoveryPerlara is a drug discovery company focused on using model organisms to find treatments for diseases previously believed to be too rare to cure. Recently Perlara entered into a drug discovery and development collaboration with Novartis, a deal that included an equity investment and is seen as validating Perlara’s platform. We spoke to Ethan Perlstein, CEO of Perlara, about the company’s unique approach to drug discovery, why it focuses on the diseases it does, and the significance of its agreement with Novartis.2016-11-1019 min

The Bio ReportNovartis Deal Validates Perlara’s Approach to Rare Disease Drug DiscoveryPerlara is a drug discovery company focused on using model organisms to find treatments for diseases previously believed to be too rare to cure. Recently Perlara entered into a drug discovery and development collaboration with Novartis, a deal that included an equity investment and is seen as validating Perlara’s platform. We spoke to Ethan Perlstein, CEO of Perlara, about the company’s unique approach to drug discovery, why it focuses on the diseases it does, and the significance of its agreement with Novartis.2016-11-1019 min

RARECastExpanding the Potential of CrowdfundingCrowdfunding, once thought of as little more than a way to raise money for small scientific projects, is increasingly being used to raise significant capital to fund startups. Perlstein Lab, a San Francisco-based starup focused on finding new drugs to treat rare diseases, raised more than $2 million using crowdfunding. We spoke to Ethan Perlstein, founder and CEO of Perlstein Lab, about his company, the potential of crowdfunding, and the unusual role social media has played in his efforts to raise capital.2015-01-1615 min

Inquiring Minds27 Ethan Perlstein - Scenes from the PostdocalypseHow do you become a scientist? Ask anyone in the profession and you'll probably hear some version of the following: get a Bachelor's of Science degree, work in a lab, get into a PhD program, publish some papers, get a good post-doctoral position, publish some more papers and then apply for a tenure-track job at a large university. It's a long road—and you get to spend those 10 to 15 years as a poor graduate student or underpaid postdoc, while you watch your peers launch careers, start families, and contribute to their 401(k) plans.And then comes the academic jo...2014-03-2854 min

SourcefabricInterview With Ethan Perlstein And Bryan Glanz, Live @ Mozilla FestivalInterview with Ethan Perlstein @eperlste and Bryan Glanz @brianglanz an open approach to news and science at Mozilla Festival.2013-11-0102 min